TD Cowen raised the firm’s price target on Exelixis (EXEL) to $38 from $34 and keeps a Buy rating on the shares. The firm said they posted a solid Q4 beat and they expect the company to stay independent but believes its pipeline is being overlooked.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $36 from $30 at Stifel
- Exelixis price target raised to $29 from $25 at Barclays
- Exelixis price target raised to $38 from $37 at Piper Sandler
- Hold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market Opportunities
- Exelixis’s Growth Potential Bolstered by Cabozantinib Expansion and Promising New Drug Developments